Kelly E. Dooley, MD, PhD, MPH
More Information
Kelly Dooley, MD, PhD, MPH, is a Professor of Medicine, and Director of the Division of Infectious Disease within the Department of Medicine at Vanderbilt University Medical Center (VUMC).
As an infectious disease specialist and clinical pharmacologist, Dr. Dooley maintains an active clinical practice in HIV care. Her research focuses on tuberculosis therapeutics with an emphasis on clinical trials of TB drugs and HIV/TB co-treatment, as well as clinical pharmacology of TB and HIV drugs. She is lead investigator for trials of therapeutics for drug-sensitive and drug-resistant TB, TB-HIV, and pediatric TB meningitis. She is on the TB scientific committees of the AIDS Clinical Trials Group and IMPAACT networks, and is a consultant to World Health Organization on TB therapeutics and pharmacology.
Dr. Dooley earned her Master of Public Health in Epidemiology from University of North Carolina at Chapel Hill, and her medical degree from Duke University. She completed her Internal Medicine residency, and fellowships in Infectious Diseases and Clinical Pharmacology at Johns Hopkins University. She subsequently earned a PhD in Clinical Investigation at the Johns Hopkins Bloomberg School of Public Health. She joined VUMC in 2022, and is board certified in internal medicine and infectious diseases.
Research Information
Rifat, D; Prideaux, B; Savic, RM; Urbanowski, ME; Parsons, TL; Luna, B; Marzinke, MA; Ordonez, AA; Demarco, VP; Jain, SK; Dartois, V; Bishai, WR; Dooley, KE. Using rabbits with cavitary disease and translational PK/PD modeling to understand TB trial results. Science Translational Medicine (2018) 10: eaai7786. PMC5969904.
Dooley, KE; Miyahara, S; von Groote-Biglingmaier, F; Sun, X; Hafner, R; Rosenkranz, SL; Ignatius, EH; Nuermberger, EL; Moran, L; Donahue, K; Swindells, S; Vanker, N; Diacon, AH; and the A5312 Study Team. Early Bactericidal Activity of Different Isoniazid Doses for Drug Resistant TB (INHindsight): A Randomized Open-label Clinical Trial. American Journal of Respiratory and Critical Care Medicine (2020) 201: 1579-1580.
Dooley KE, Rosenkranz SL, Conradie F, Moran L, Hafner R, von Groote-Bidlingmaier F, Lama J, Shenje J, de los Rios J, Comins K, Morganroth J, Diacon A, Cramer YS, Donahue K, Maartens G, and the AIDS Clinical Trials Group (ACTG) A5343 DELIBERATE Study Team. QT effects of bedaquiline, delamanid or both in patients with rifampicin–resistant TB: a randomized controlled trial. Lancet Inf Dis, (2021) 21: 975-983
Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, Dooley KE, Engle M, Goldberg SV et al. ACTG/TBTC. Four-month rifapentine regimens with or without moxifloxacin for tuberculosis. New England Journal of Medicine, (2021) 384: 1705-1718.
Svensson, EM; Aweeka , F; Park, J-G; Marzan, F; Dooley, KE*§; Karlsson, MO* Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients co-infected with HIV and tuberculosis. Antimicrobial Agents and Chemotherapy (2013) 57: 2780-2787. PMC3716161.
Dooley, KE; Luetkemeyer, AF; Park, J-G; Allen, R; Cramer, Y; Murray, S; Sutherland, D; Aweeka, F; Koletar, SL; Marzan, F; Bao, J; Savic R; Haas, DW; ACTG A5306 Study Team. Phase I safety, PK, and pharmacogenetics study of the anti-TB drug PA-824 with concomitant lopinavir/ritonavir, efavirenz, or rifampin. Antimicrobial Agents Chemotherapy (2015) 58: 5245-52. PMC4135849.
Dooley, KE; Kaplan, R; Mwelase, N; Grinsztejn, B; Ticona, E; Lacerda, M; Sued, O; Belonosova, E; Ait-Khaled, M; Angelis, K; Brown, D; Singh, R; Talarico, CL; Tenorio, AR; Keegan, MR; Aboud, M; and the INSPIRING study group. Dolutegravir-based antiretroviral therapy for patients co-infected with tuberculosis and HIV: a multicenter, noncomparative, open-label, randomized trial. Clin Inf Diseases 2020; 70(4):549-556.
Dooley, KE; Savic, R; Gupte, A; Marzinke, MA; Zhang, N; Edward, VA; Wolf, L; Sebe, M; Likoti, J; Fyvie, MJ; Shibambo, I; Beattie, T; Chaisson, RE; Churchyard, GJ; DOLPHIN Study Team. Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients withHIV taking dolutegravir-based antiretroviral therapy: a phase I/II trial. Lancet HIV 2020. 7: e401-e409
Dooley, KE; Denti, P; Martinson, N; Cohn, S; Mashabela, F; Hoffmann, J; Haas, DW, Hull, J; Msandiwa, R; Castel, S; Wiesner, L; Chaisson, RE, McIlleron, H. Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis co-infection. Journal of Infectious Diseases (2015) 211: 197-205. PMC4334832.
McIlleron, H; Denti, P; Cohn, S; Mashabela, F; Hoffmann, J; Shembe, S; Msandiwa, R; Wiesner, L; Velaphi, S; Lala, S; Chaisson, R; Martinson, N; Dooley, KE. Prevention of tuberculosis using rifampicin plus isoniazid reduces nevirapine concentrations in HIV-exposed infants. Journal of Antimicrobial Chemotherapy (2017) 72: 2028-2034. PMC5890683.
Mathad JS, Savic R, Britto P, Jayachandran P, Wiesner L, Montepiedra G, Norman J, Zhang N, Townely E, Chakhtoura N, Bradford S, Patil S, Popson S, Chipato T, Rouzier V, Langat D, Chalermchockcharoentkit A, Kamthunzi P, Gupta A, Dooley KE: IMPAACT 2001 Study Team. Pharmacokinetics and safety of three months of weekly rifapentine and isoniazid for tuberculosis prevention in pregnant women. Clin Inf Dis, in press.
Paradkar, MS; D, BD; Mvalo, T; Arenivas, A; Thakur, KT; Wolf, L; Nimkar, S; Inamdar, S; Giridharan, P; Selladurai, E; Kinikar, A; Valvi, C; Khwaja, S; Gadama, D; Balaji, S; Kattagoni, KY; Venkatesan, M; Savic, R; Swaminathan, S; Gupta, A; Gupte, N; Mave, V; Dooley KE; for the TBM-KIDS Study Team. Randomized clinical trial of high dose rifampicin with or without levofloxacin versus standard of care for paediatric tuberculous meningitis: the TBM-KIDS Trial. Clin Inf Dis, in press.
